&w=3840&q=100)
Lincoln Pharma Q1 results: Profit up 17% to ₹28 cr, share jumps 8.5%
Total income rose by 7.3 per cent to ₹169.34 crore in the first quarter of FY26 compared to ₹157.69 crore in the year-ago period, the company said in a statement.
"EBITDA for Q1 FY26 was reported at ₹39.08 crore as compared to EBITDA of ₹33.14 crore in Q1 FY25, growth of 17.92 per cent Y-o-Y, the statement said.
The company is targeting a revenue of ₹1,000 crore within the next three years, driven by business expansion into high-value product lines and entry into new markets, Lincoln Pharmaceuticals Managing Director Mahendra Patel said.
This goal is part of a broader strategy to achieve a 15-18 per cent annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments, Patel added.
During the first quarter, the company started its bulk drug manufacturing plant, he said, adding that the company has received approvals for 10 products and others are under process. The company has invested ₹4 crore for this plant from internal accruals.
Shares of the company jumped by 8.47 per cent to close at at ₹576.90 apiece on BSE.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
38 minutes ago
- News18
AFCOMs Q1 FY26 mirrors H2 FY25 performance setting tone for a strong year ahead
PNNChennai (Tamil Nadu) [India], August 11: AFCOM Holdings Limited (AFCOM), (BSE – 544224), an integrated air cargo solutions company with operations across domestic and international routes. The Company has announced its Unaudited Financial Results for Q1 Financial Highlights– Total Income of ₹ 11,889.0 Cr, YoY growth of 198.1%– EBITDA of ₹ 3,664.7 Cr, YoY growth of 2,401.8%– Net Profit of ₹ 2,707.0 Cr, YoY growth of 4,255.5%– EPS of ₹ 10.9, YoY growth of 3,102.9%Commenting on this partnership, Capt. Deepak Parasuraman & Chairman & Managing Director of AFCOM Holdings Limited, said, 'We are pleased to commence quarterly financial disclosures from Q1 FY26, a decision guided by our investor community's request for more frequent updates and in line with our commitment to transparency. This shift enables us to better reflect the Company's ongoing initiatives and operational developments across each cargo aviation industry is currently experiencing increased activity, driven by a higher freight rates and evolving trade dynamics. Afcom has maintained strong operational performance with a current network utilization of approximately 84%. We continue to expand into newer high-value sectors, strengthen our presence across key domestic and international hubs, and deepen interline partnerships to enhance cargo connectivity and turnaround efficiency.A notable milestone was the launch of our new route to Hanoi, Vietnam, an interline agreement with Viet Jet to enable broader connectivity in the ASEAN region. These developments form part of our Phase 2 growth roadmap. Looking ahead, we remain focused on scaling operations through additional fleet additions, deeper international coverage, and technology-led enhancements." (ADVERTORIAL DISCLAIMER: The above press release has been provided by PNN. ANI will not be responsible in any way for the content of the same)
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Yatharth hits new high, zooms 52% in 3 months; what's driving the rally?
Yatharth Hospital & Trauma Care Services share price today: Shares of Yatharth Hospital & Trauma Care Services (Yatharth Hospitals) hit a new high of ₹738, as they rallied nearly 5 per cent on the BSE in Monday's intra-day trade. In the past two weeks, the stock price of one of the leading private super speciality hospitals in North India has surged 20 per cent. In the past three months, it zoomed 52 per cent. In the past six months, the stock rallied nearly 80 per cent, as compared to 5 per cent rise in the BSE Sensex. What's the trigger behind the rally in Yatharth Hospitals? Yatharth Hospitals is set to be included as a constituent of the MSCI India Small Cap Index, effective from the upcoming index rebalancing date of August 26, 2025. The MSCI India Small Cap Index is designed to measure the performance of the small cap segment of the Indian equity market. The MSCI indices are widely tracked by international institutional investors, and this addition is set to enhance the Yatharth Hospital's visibility amongst global investors, the company said in a press release. Over the past four years, Yatharth Hospitals has delivered a robust revenue compounded annual growth rate (CAGR) of 40 per cent and a profit after tax (PAT) CAGR of 61 per cent. This remarkable growth underscores the increasing influence of the Yatharth brand and its position as a leading healthcare provider in North India. The company's success is attributed to significant investments in state-of-the-art medical technologies, focus on clinical excellence and the dedication of its medical practitioners and staff, it said. Yatharth Hospitals is on course to surpass its target of 3,000 beds by FY28, driven by a strategic capacity expansion focused on strengthening its footprint in the highgrowth Delhi-NCR region. The new hospitals in Faridabad and New Delhi will offer super-specialty services from day one, ensuring higher average revenue per occupied bed (ARPOB) and enabling a faster ramp-up. With Ebitda breakeven anticipated within 12–15 months of commissioning, this expansion is expected to propel robust volume growth and enhance operating leverage, according to analysts at Choice Equity Broking. 'We expect growth to be driven by higher ARPOB, improved occupancy levels (aiming for 70 per cent across existing facilities), strategic acquisitions, and a sustained revenue growth trajectory of +30 per cent. Additionally, an increasing share of super-specialty services is anticipated to enhance their contribution to Yatharth's overall revenues,' the brokerage firm said with a 'buy' rating on stock and target price of ₹800 per share. In the coming years, healthcare delivery in India is expected to be primarily shaped by technological advancements and the growing adoption of digital health solutions by both providers and patients. This transformation will be fueled by shifts in mindset, advancements in technology, infrastructure development, government initiatives, and more. Key government programmes, such as the Ayushman Bharat Digital Mission (ABDM) and e-Sanjeevani, are laying the groundwork for a digitised healthcare ecosystem. At the same time, private sector players are exploring digital technologies like robotics, telehealth, AI, and 5G to offer technology-driven care to their patients. Overall, the Indian healthcare industry has maintained robust growth momentum and is poised for continued expansion, fuelled by strong government support, rising private sector investments, technological advancements, and a steadfast commitment to enhancing healthcare access and affordability for all segments of the population, Fortis Healthcare said in FY25 annual report. About Yatharth Hospital & Trauma Care Services Yatharth Hospitals is one of North India's leading healthcare providers. With seven super speciality hospitals located in North India, i.e., at Noida, Greater Noida, Noida Extension, Greater Faridabad, newly operationalised Model Town facility, and soon to be operationalised Faridabad facility in Delhi NCR, and Jhansi-Orchha in Madhya Pradesh, it has a total capacity of more than 2,300 beds.
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
JSW Cement IPO sees modest demand, fully booked on Day 3; GMP flat
JSW Cement IPO subscription status Day 3: The initial public offering (IPO) of JSW Cement, part of the diversified JSW Group, will close for public subscription today, August 11, 2025. The ₹3,600 crore public issue opened for subscription on Thursday, August 7, and has seen a lacklustre response from investors. However, it managed to sail through the full subscription mark on the last day of bidding. As of 12:45 PM on Monday, data from the National Stock Exchange (NSE) shows that the IPO attracted bids for 221.4 million equity shares compared to 181.29 million shares on offer. This translates to an overall subscription rate of only 1.22 times. Among the individual categories, non-institutional investors (NIIs) placed the highest number of bids, oversubscribing their reserved category by 1.64 times. This was followed by qualified institutional buyers (QIBs), who bid 1.11 times, and the retail investors portion was booked at only 1.1 times. JSW Cement IPO GMP On the final day of subscription, JSW Cement's unlisted shares were commanding a marginal premium in the grey market. Sources tracking unofficial market activity revealed the shares were trading at ₹151 per share, reflecting a GMP of only ₹4 or 2.7 per cent, over the upper end of the price band of ₹139 to ₹147. JSW Cement IPO Review Analysts at Canara Bank Securities and Anand Rathi Research recommend subscribing to the issue, citing the company's growth potential, sustainability focus, and strategic alignment within the JSW Group. AUM Capital has also assigned a Subscribe rating to the issue. READ MORE JSW Cement IPO details The public offering of JSW Cement comprises a combination of a fresh issue of 108.8 million equity shares and an offer-for-sale (OFS) of 136.1 million shares. The IPO is priced in the range of ₹139-147 per share, with a lot size of 102 shares. Investors can bid for a minimum of 102 shares and in multiples thereof. A retail investor would need a minimum of ₹14,994 to bid for one lot at the upper end price. The maximum limit for retail investors is 13 lots (1,326 shares), amounting to an investment of ₹1,94,922. As the IPO closes for subscription today, the basis of allotment is expected to be finalised on Tuesday, August 12. Shares are expected to be credited to investors' demat accounts on Wednesday, August 13. JSW Cement shares are tentatively set to list on the BSE and NSE on Thursday, August 14. Kfin Technologies is the registrar of the issue. Axis Capital, JM Financial, Citigroup Global, DAM Capital, Goldman Sachs (India), Jefferies India, Kotak Mahindra Capital, and SBI Capital Markets are the book-running lead managers. According to the red herring prospectus, the company plans to use the net fresh issue proceeds for setting up a new integrated cement plant in Nagaur (Rajasthan), repayment of debt and general corporate purposes.
